Celen Sofie, de Groot Tjibbe, Balzarini Jan, Vunckx Kathleen, Terwinghe Christelle, Vermaelen Peter, Van Berckelaer Lizette, Vanbilloen Hubert, Nuyts Johan, Mortelmans Luc, Verbruggen Alfons, Bormans Guy
Laboratory for Radiopharmacy, K.U. Leuven, B-3000 Leuven, Belgium.
Nucl Med Biol. 2007 Apr;34(3):283-91. doi: 10.1016/j.nucmedbio.2007.01.003.
Cytosolic thymidine kinase (TK1) catalyzes phosphorylation of thymidine to its monophosphate. TK1 activity is closely related with DNA synthesis, and thymidine analogs derivatized with bulky carboranylalkyl groups at the N-3 position were reported to be good substrates for TK1. Accordingly, we have synthesized (99m)Tc-MAMA-propyl-thymidine and evaluated it as a potential tumor tracer.
The bis(S-trityl)-protected MAMA-propyl-thymidine precursor (3-N-[S-trityl-2-mercaptoethyl]-N-[N'-(S-trityl-2-mercaptoethyl)amidoacetyl]-aminopropyl-thymidine) was prepared in three steps, and its structure was confirmed with (1)H NMR and mass spectrometry. Deprotection of the thiols and labeling with (99m)Tc were done in a two-step, one-pot procedure, yielding (99m)Tc-MAMA-propyl-thymidine, which was analyzed with high-performance liquid chromatography, radio-LC-MS analysis (ESI+) and electrophoresis, and its log P was determined. The biodistribution in normal mice was evaluated, and its biodistribution in a radiation-induced fibrosarcoma (RIF) tumor mouse was compared with that of 3'-deoxy-3'-[(18)F] fluorothymidine [(18)F]FLT.
(99m)Tc-MAMA-propyl-thymidine was obtained with a radiochemical yield of 70%. Electrophoresis indicated that the complex is uncharged, and its log P was 1.0. The molecular ion mass of the Tc complex was 589 Da, which is compatible with the hypothesized N(2)S(2)-oxotechnetium structure. Tissue distribution showed fast clearance from plasma primarily by the hepatobiliary pathway. Whole-body planar imaging after injection of (99m)Tc-MAMA-propyl-thymidine in an RIF tumor-bearing mouse showed high uptake in the liver and the intestines. No uptake was observed in the tumor, in contrast to the clear uptake observed for [(18)F] FLT visualized with muPET.
Although it has been reported that TK1 accepts large substituents at the N-3 position of the thymine ring, the results of this study show that (99m)Tc-MAMA-propyl-thymidine cannot be used as a single photon emission computed tomography tumor tracer, probably because the (99m)Tc-MAMA ligand is too bulky to be tolerated by TK1.
胞质胸苷激酶(TK1)催化胸苷磷酸化为其单磷酸酯。TK1活性与DNA合成密切相关,据报道,在N-3位用大体积碳硼烷基烷基衍生化的胸苷类似物是TK1的良好底物。因此,我们合成了(99m)Tc-MAMA-丙基胸苷,并将其评估为一种潜在的肿瘤示踪剂。
双(S-三苯甲基)保护的MAMA-丙基胸苷前体(3-N-[S-三苯甲基-2-巯基乙基]-N-[N'-(S-三苯甲基-2-巯基乙基)氨基乙酰基]-氨基丙基胸苷)分三步制备,其结构通过(1)H NMR和质谱确证。硫醇的脱保护和用(99m)Tc标记通过两步一锅法完成,得到(99m)Tc-MAMA-丙基胸苷,用高效液相色谱、放射性液相色谱-质谱分析(ESI+)和电泳对其进行分析,并测定其log P。评估其在正常小鼠体内的生物分布,并将其在辐射诱导的纤维肉瘤(RIF)肿瘤小鼠体内的生物分布与3'-脱氧-3'-[(18)F]氟胸苷[(18)F]FLT的生物分布进行比较。
获得了放射化学产率为70%的(99m)Tc-MAMA-丙基胸苷。电泳表明该配合物不带电荷,其log P为1.0。Tc配合物的分子离子质量为589 Da,与假设的N(2)S(2)-氧代锝结构相符。组织分布显示主要通过肝胆途径从血浆中快速清除。在荷RIF肿瘤小鼠中注射(99m)Tc-MAMA-丙基胸苷后进行的全身平面显像显示肝脏和肠道摄取较高。与用μPET显像观察到的[(18)F]FLT的明显摄取不同,在肿瘤中未观察到摄取。
尽管已有报道称TK1接受胸腺嘧啶环N-3位的大取代基,但本研究结果表明(99m)Tc-MAMA-丙基胸苷不能用作单光子发射计算机断层扫描肿瘤示踪剂,可能是因为(99m)Tc-MAMA配体体积太大,TK1无法耐受。